Factors predicting one-year mortality in amyotrophic lateral sclerosis patients--data from a population-based registry

Joachim Wolf, Anton Safer, Johannes C Wöhrle, Frederick Palm, Wilfred A Nix, Matthias Maschke, Armin J Grau, Joachim Wolf, Anton Safer, Johannes C Wöhrle, Frederick Palm, Wilfred A Nix, Matthias Maschke, Armin J Grau

Abstract

Background: Survival in amyotrophic lateral sclerosis varies considerably. About one third of the patients die within 12 months after first diagnosis. The early recognition of fast progression is essential for patients and neurologists to weigh up invasive therapeutic interventions. In a prospective, population-based cohort of ALS patients in Rhineland-Palatinate, Germany, we identified significant prognostic factors at time of diagnosis that allow prediction of early death within first 12 months.

Methods: Incident cases, diagnosed between October 2009 and September 2012 were enrolled and followed up at regular intervals of 3 to 6 months. Univariate analysis utilized the Log-Rank Test to identify association between candidate demographic and disease variables and one-year mortality. In a second step we investigated a multiple logistic regression model for the optimal prediction of one-year mortality rate.

Results: In the cohort of 176 ALS patients (mean age 66.2 years; follow-up 100%) one-year mortality rate from diagnosis was 34.1%. Multivariate analysis revealed that age over 75 years, interval between symptom onset and diagnosis below 7 months, decline of body weight before diagnosis exceeding 2 BMI units and Functional Rating Score below 31 points were independent factors predicting early death.

Conclusions: Probability of early death within 12 months from diagnosis is predicted by advanced age, short interval between symptom onset and first diagnosis, rapid decline of body weight before diagnosis and advanced functional impairment.

Trial registration: ClinicalTrials.gov (NCT01955369, registered September 28, 2013).

Figures

Figure 1
Figure 1
Mortality rate one year after first diagnosis (FD) of ALS by FRS at FD. Observed rates: bubble area proportional to number of observations; black dots: logistic function estimate.

References

    1. Logroscino G, Traynor BJ, Hardiman O, Chio A, Couratier P, Mitchell JD, Swingler RJ, Beghi E. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry. 2008;79:6–11. doi: 10.1136/jnnp.2006.104828.
    1. Millul A, Beghi E, Logroscino G, Micheli A, Vitelli E, Zardi A. Survival of patients with amyotrophic lateral sclerosis in a population-based registry. Neuroepidemiology. 2005;25:114–119. doi: 10.1159/000086353.
    1. Del Aguila MA, Longstreth WT, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis. A population-based study. Neurology. 2003;60:813–819. doi: 10.1212/01.WNL.0000049472.47709.3B.
    1. Chio A, Logroscino G, Hardiman O, Swingler RJ, Mitchell D, Beghi E, Traynor B. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009;10:310–323. doi: 10.3109/17482960802566824.
    1. Census data 2011 of Rhineland-Palatinate..
    1. Wolf J, Wöhrle JC, Palm F, Nix WA, Maschke M, Safer A, Becher H, Grau AJ. Incidence of amyotrophic lateral sclerosis in Rhineland-Palatinate, Germany. Amyotroph Lateral Scler. 2014;15:269–74. doi: 10.3109/21678421.2014.887733.
    1. Ross MA, Miller RG, Berchert L, Parry G, Barohn RJ, Armon C, Bryan WW, Petajan J, Stromatt S, Goodpasture J, McGuire D. Toward earlier diagnosis of amyotrophic lateral sclerosis: revised criteria. Neurology. 1998;50:768–772. doi: 10.1212/WNL.50.3.768.
    1. The ALS, CNTF treatment study (ACTS) phase I-II Study Group The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol. 1996;53:141–147. doi: 10.1001/archneur.1996.00550020045014.
    1. Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, Lepore V, Simone IL, Lamberti P, Serlenga L, Logroscino G. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: A population-based study. J Neurol Neurosurg Psychiatry. 2008;79:33–37. doi: 10.1136/jnnp.2007.118018.
    1. Chio A, Mora G, Leone M, Mazzini L, Cocito D, Giordana MT, Bottacchi E, Mutani R. Early symptom progression rate is related to ALS outcome. A prospective population-based study. Neurology. 2002;59:99–103. doi: 10.1212/WNL.59.1.99.
    1. Czaplinski A, Yen AA, Appel SH. Amyotrophic lateral sclerosis: early predictors of prolonged survival. J Neurol. 2006;253:1428–1436. doi: 10.1007/s00415-006-0226-8.
    1. Beghi E, Millul A, Logroscino G, Vitelli E, Micheli A. Outcome measures and prognostic indicators in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2008;9:163–167. doi: 10.1080/17482960801942695.
    1. Marin B, Desport JC, Kajeu P, Jesus P, Nicolaud B, Nicol M, Preux PM, Couratier P. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry. 2011;82:628–634. doi: 10.1136/jnnp.2010.211474.
    1. Shimizu T, Nagaoka U, Nakayama Y, Kawata A, Kugimoto C, Kuroiwa Y, Kawai M, Shimohata T, Nishizawa M, Mihara B, Arahata H, Fujii N, Namba R, Ito H, Imai T, Nobukuni K, Kondo K, Ogino M, Nakajima T, Komori T. Reduction rate of body mass index predicts prognosis for survival in amyotrophic lateral sclerosis: a multicenter study in Japan. Amyotroph Lateral Scler. 2012;13:363–366. doi: 10.3109/17482968.2012.678366.
    1. Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, Rowland LP, Levin B, Mitsumoto H. The ALSFRS-R predicts survival time in an ALS clinic population. Neurology. 2005;64:38–43. doi: 10.1212/01.WNL.0000148648.38313.64.
    1. Magnus T, Beck M, Giess R, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve. 2002;25:709–714. doi: 10.1002/mus.10090.
    1. Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, Shinoda K, Sugino M, Hanafusa T. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66:265–267. doi: 10.1212/01.wnl.0000194316.91908.8a.
    1. Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R, Mohammadi B. ALSFRS-R score and its ratio: a useful predictor for ALS progression. J Neurol Sci. 2008;275:69–73. doi: 10.1016/j.jns.2008.07.016.
    1. Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2006;77:390–392. doi: 10.1136/jnnp.2005.072660.

Source: PubMed

3
Subskrybuj